Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 40
Healthy volunteers: yes

Brief summary:
This study will look at how a single dose of abemaciclib will impact the body's ability to get rid of two other drugs, metformin and iohexol. In addition, this study will evaluate the effect of a single dose of abemaciclib on kidney function by measuring blood and urine markers. Side effects will also be documented.

Each participant will complete four study periods. During each study period, participants will stay in the clinical research unit for nine days and eight nights.

The study will last approximately 10 weeks, not including screening. Screening is required within 28 days prior to the start of the study.

This study is for research purposes only and is not intended to treat any medical condition.

Detailed description:

Arms:
arm 1: Single dose of placebo administered orally followed by a single dose of metformin administered orally in one of four study periods. arm 2: Single dose of abemaciclib administered orally followed by a single dose of metformin administered orally in one of four study periods. arm 3: Single dose of placebo administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods. arm 4: Single dose of abemaciclib administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.

Interventions: intervention 1: Abemaciclib intervention 2: Metformin intervention 3: Iohexol intervention 4: Placebo
Intervention descriptions: intervention 1: Administered orally intervention 2: Administered orally intervention 3: Administered intravenously (IV) intervention 4: Administered orally

Protocol document: